"Our products are built from our proprietary genetic databases, which are used to identify diagnostic and prognostic biomarkers for cancer.
Our intellectual property covers the areas of bladder, gastric, colorectal and endometrial cancers and melanoma; however, our commercial focus is on bladder cancer products for the short to medium term. Our wider portfolio is expected to provide us with further options in the future."
Price at posting:
78.0¢ Sentiment: None Disclosure: Not Held
